It is a privately held biotechnology company with corporate headquarters and research and development facilities near Princeton, NJ. The Company has eight U.S. patents covering microtransponder-based assays and technology and several more patents pending. PharmaSeq's strategy is to apply microtransponder technology to DNA probe diagnostics, single nucleotide polymorphism (SNP) detection, and proteomics. The Company will then move forward in other aspects of genomics, as well as pharmaceutical drug discovery, combinatorial chemistry, radio frequency identification (RFID) and related areas.